Jayastu Senapati, M.B.B.S., M.D., D.M.
Department of Leukemia, Division of Cancer Medicine
About Dr. Jayastu Senapati
Dr. Senapati is an Assistant Professor in the Dept of Leukemia at the University of Texas MD Anderson Cancer Center, Houston Texas. He graduated from the Christian Medical College at Vellore in India followed by further residency in Internal Medicine in the same institution followed by Clinical Hematology fellowship at AIIMS, New Delhi. He subsequently did a leukemia fellowship at MD Anderson Cancer Center and joined the department as faculty. Dr. Senapati treats patients with acute and chronic leukemias and focuses on management of critical acute leukemia patients. He believes in patient centric leukemia care, that is driven by the latest research and evidence-based medicine. His research focus is primarily on acute myeloid leukemia and acute lymphoblastic leukemia, and he has been involved in several clinical trials and research projects. He has important publications on leukemia therapy and management in high-impact journals like Lancet Haematology, Journal of Clinical Oncology, Blood, Leukemia, Clinical Cancer Research, Blood Cancer Journal, Cancer, Haematologica amongst others. He has presented several important data in national and international conferences like American Society of Hematology, American Society of Clinical Oncology and European Hematology Association annual meetings. During his medical training, residency, and fellowships he has received several awards including a coveted National Scholarship by the Govt. of India, S.C. Devadutta Award in Biochemistry, Paul Harrison Award in Neurology, J.C.M. Shastry Award in nephrology, P.H. Chandrashekhar Gold Medal in Infections Diseases, Mammen Chandy Gold Medal in Hematology, Post Graduate Gold Medal in Rheumatology, M.S Seshadri Award in Endocrinology, amongst others. During his leukemia fellowship at MD Anderson Cancer Center, he received the Best Leukemia Research Fellow of the Year Award and Best Leukemia Clinical Fellow of the Year Award in successive years. Dr. Senapati works with a team of well-trained and empathetic nurses and mid-level providers whose primary focus is to offer the best treatment approach for their patients and holistic care.
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
AML- Acute Myeloid Leukemia
ALL- Acute Lymphoblastic Leukemia MPAL- Mixed Phenotypic Acute Leukemia
Clinical Interests
AML- Acute Myeloid Leukemia
ALL- Acute Lymphoblastic Leukemia MPAL- Mixed Phenotypic Acute Leukemia CML- Chronic Myeloid Leukemia CLL- Chronic Lymphocytic Leukemia AA- Aplastic Anemia
Education & Training
Degree-Granting Education
| 2012 | Christian Medical College, Vellore, IND, MBBS, MD |
Postgraduate Training
| 2021-2023 | Clinical Fellowship, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2018-2021 | Clinical Fellowship, D. M. Clinical Hematology, All India Institute of Medical Sciences, New Delhi |
| 2015-2018 | Clinical Residency, Internal Medicine, Christian Medical College, Vellore |
Board Certifications
| 2023 | Texas Medical Board |
Honors & Awards
| 2022 | ASCO Conquer Cancer abstract achievement Award, American Society of Clinical Oncology |
| 2022 | American Society of Hematology Abstract Achievement Award, American Society of Hematology |
| 2016 | M. S. Seshadri prize in Endocrinology for postgraduate students in MD Medicine/Pediatrics, Christian Medical College, Vellore |
| 2016 | Postgraduate Gold Medal in Hematology, Christian Medical College, Vellore |
| 2015 | Dr. P.H. Chandrasekhar Gold Medal in Infectious disease, Christian Medical College, Vellore |
| 2011 | J.C.M Shastry award in Nephrology, Christian Medical College, Vellore |
| 2011 | Indian Academy of Pediatrics divisional and state topper, Indian Academy of Pediatrics |
| 2010 | S. C Devadutta prize in Biochemistry, Christian Medical College, Vellore |
| 2010 | First Place National Fujio Cup Quiz, Nichi in Center for Regenerative Medicine |
| 2009 | Paul Harrison prize in Neurology, Christian Medical College, Vellore |
| 2007 | National Biology Olympian, Tata Institute of Fundamental Research |
| 2005 | National Scholar under National Talent Search examination, National Council of Education Research and Training (N.C.E.R.T.), Govt. of India |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Senapati J, Fiskus WC, Daver N, Wilson NR, Ravandi F, Garcia-Manero G, Kadia T, DiNardo CD, Jabbour E, Burger J, Short NJ, Alvarado Y, Jain N, Masarova L, Issa GC, Qiao W, Khoury JD, Pierce S, Miller D, Sasaki K, Konopleva M, Bhalla KN, Borthakur G, Pemmaraju N. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clin Cancer Res 29(21):4352-4360, 2023. PMID: 37585491.
- Senapati J, Kadia TM, Ravandi F. Maintenance therapy in acute myeloid leukemia: advances and controversies. Haematologica 108(9):2289-2304, 2023. e-Pub 2023. PMID: 37139599.
- Senapati J, Panda T, Rajendra A, Aggarwal M. Understanding the barriers to AML care in India. Lancet Haematol 10(9):e710-e711, 2023. PMID: 37652600.
- Desikan SP, Senapati J, Jabbour E, Abuasab T, Short N, Tang G, Wang S, Kebriaei P, Kadia T, Borthakur G, Ravandi F, Roberts K, Mullighan C, Konopleva M, Kantarjian H, Jain N. Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia. Am J Hematol 98(6):E142-E144, 2023. e-Pub 2023. PMID: 36877196.
- Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban Bravo G, Sasaki K, Kadia TM, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol 10(6):e433-e444, 2023. e-Pub 2023. PMID: 37187201.
- Senapati J, Muftuoglu M, Ishizawa J, Abbas HA, Loghavi S, Borthakur G, Yilmaz M, Issa GC, Dara SI, Basyal M, Li L, Naqvi K, Pourebrahim R, Jabbour EJ, Kornblau SM, Short NJ, Pemmaraju N, Garcia-Manero G, Ravandi F, Khoury J, Daver N, Kantarjian HM, Andreeff M, DiNardo CD. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J 13(1):101, 2023. e-Pub 2023. PMID: 37386016.
- Senapati J, Jabbour E, Konopleva M, Short NJ, Tang G, Daver N, Kebriaei P, Kadia T, Pemmaraju N, Takahashi K, DiNardo C, Sasaki K, Borthakur G, Thakral B, Kanagal-Shamanna R, Patel K, Ravandi F, Roberts K, Mullighan C, Kantarjian H, Jain N. Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements. JCO Precis Oncol 7:e2200707, 2023. PMID: 37196217.
- Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv 7(10):1958-1966, 2023. PMID: 36287248.
- Senapati J, Sasaki K, Issa GC, Lipton JH, Radich JP, Jabbour E, Kantarjian HM. Management of chronic myeloid leukemia in 2023 - common ground and common sense. Blood Cancer J 13(1):58, 2023. e-Pub 2023. PMID: 37088793.
- Senapati J, Abuasab T, Haddad FG, Ravandi F, Kadia T, DiNardo C, Daver N, Pemmaraju N, Alvarado Y, Brandt MA, Kantarjian H, Borthakur G. Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. Am J Hematol 98(3):E53-E56, 2023. e-Pub 2022. PMID: 36565294.
- Boddu PC, Senapati J, Ravandi-Kashani F, Jabbour EJ, Jain N, Ayres M, Chen Y, Keating MJ, Kantarjian HM, Gandhi V, Kadia TM. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies. Cancer 129(4):580-589, 2023. e-Pub 2022. PMID: 36448227.
- Senapati J, Jabbour E, Kantarjian H, Short NJ. Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. Leukemia 37(1):5-17, 2023. e-Pub 2022. PMID: 36309558.
- Senapati J, Verstovsek S, Masarova L, Pemmaraju N, Patel KP, Montalban-Bravo G, Pierce SA, Zhou L, Garcia-Manero G, Kantarjian HM, Bose P. Impact of SF3B1 mutation in myelofibrosis. Leuk Lymphoma 63(11):2701-2705, 2022. e-Pub 2022. PMID: 35787095.
- Pemmaraju N, Wilson NR, Senapati J, Economides MP, Guzman ML, Neelapu SS, Kazemimood R, Davis RE, Jain N, Khoury JD, Sugita M, Cai T, Smith J, Frattini MG, Garton A, Roboz G, Konopleva M. CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights. Leuk Res 121:106928, 2022. e-Pub 2022. PMID: 35963025.
- Senapati J, Shoukier M, Garcia-Manero G, Wang X, Patel K, Kadia T, Ravandi F, Pemmaraju N, Ohanian M, Daver N, DiNardo C, Alvarado Y, Aldrich J, Borthakur G. Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. Am J Hematol 97(5):574-582, 2022. e-Pub 2022. PMID: 35150150.
- Senapati J, Sasaki K. Chromosomal Instability in Chronic Myeloid Leukemia: Mechanistic Insights and Effects. Cancers (Basel) 14(10), 2022. e-Pub 2022. PMID: 35626137.
- Senapati J, Devasia AJ, Korula A, Fouzia NA, Kulkarni U, Lakshmi KM, Lionel S, Abraham A, Srivastava A, Mathews V, George B. Disease Status at Transplant has a Significant Impact on Outcomes of Autologous Transplantation (ASCT) in Patients with Hodgkin Lymphoma-A Single Center Experience. Indian J Hematol Blood Transfus 38(2):290-298, 2022. e-Pub 2021. PMID: 35496963.
- Senapati J, Kadia TM. Which FLT3 Inhibitor for Treatment of AML?. Curr Treat Options Oncol 23(3):359-380, 2022. e-Pub 2022. PMID: 35258791.
- Senapati J, Daver NG, Pemmaraju N. Antibody-Drug Conjugates in Myeloid Leukemias. Cancer J 28(6):454-461, 2022. PMID: 36383908.
- Senapati J, Dhawan R, Aggarwal M, Kumar P, Kumar Vishwanathan G, Dass J, Tyagi S, Mahapatra M, Seth T. Venetoclax and azacitidine (VenAZA) combination therapy in young unfit patients with AML: a perspective from a developing country. Leuk Lymphoma 62(6):1514-1517, 2021. e-Pub 2021. PMID: 33448885.
- Senapati J, Aggarwal M, Louis L, Mirza SA, Kumar P, Dhawan R, Dass J, Vishwanathan GK, Pandey HC, Coshic P, Tyagi S, Seth T, Mahapatra M. Transfusion practices during the COVID-19 pandemic: An experience from a hematology daycare in India. Transfus Apher Sci 60(2):103025, 2021. e-Pub 2020. PMID: 33353804.
Patient Reviews
CV information above last modified July 31, 2024